Guest Blog from Hanson Wade
Last week as part of their ‘Payer Strategies for Emerging Markets’ initiative, Hanson Wade published a report offering a valuable insight into the experiences of leading industry and healthcare experts working within emerging markets.
The report provided some fascinating results. For instance, of the drug developers, academics, payers and solution providers asked, the overwhelming majority agreed that within the next five years, emerging markets will make up over a third of pharmaceutical company revenue.
When questioned on the barriers of growth in emerging markets, over a third thought that weak industry-payer partnerships were one of the main challenges holding them back. Although this statistic is not, in itself, that surprising, the spread of answers that was given by the remaining two thirds was certainly interesting. Follow this link to get the full report.
It is clear that the emerging markets offer huge potential for the healthcare industry, accessing and launching products in these key growth areas continues to be a source of frustration for many. The report and supplementary case study provides a rare and useful insight into the thoughts and experiences of those already working within these markets and is a must read for all those looking to expand their revenue streams internationally.